Atara looks to add $36M to its runway via direct offering
Thousand Oaks-based Atara Biotherapeutics announced that it will be hosting a $36 million registered direct offering. The gross proceeds to Atara from the offering are expected to be $36 million, before deducting estimated offering expenses payable by Atara. Atara currently intends to use the net proceeds from the offering for working capital and general corporate Read More →
Semtech shares beat Q2 estimates, stock gains 7%
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
UCSB wins $22M for new biofoundry on campus
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
AI pluses, minuses in business sectors focus of CSUCI forum
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Latigo Bio shares positive news, appoints chief medical officer
Thousand Oaks-based Latigo Biotherapeutics, a company with the mission of creating non-opioid pain medication, shared positive phase 1 results for its lead candidate. In its phase 1 clinical trial, data from LTG-001 showed that the oral treatment aimed to treat acute and chronic pain at its source was “well tolerated with rapid absorption.” The trial Read More →
Ventura fiber optics firm sells operations
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen doubles down on India biotech
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
